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Abstract 
Study Design: A randomized, double-blind, controlled trial.  
Objective: To determine the clinical effectiveness of therapeutic lumbar facet joint nerve 
blocks with or without steroids in managing chronic low back pain of facet joint origin. 
Summary of Background Data: Lumbar facet joints have been shown as the source of 
chronic pain in 21% to 41% of low back patients with an average prevalence of 31% utilizing 
controlled comparative local anesthetic blocks. Intraarticular injections, medial branch blocks, 
and radiofrequency neurotomy of lumbar facet joint nerves have been described in the al-
leviation of chronic low back pain of facet joint origin. 
Methods: The study included 120 patients with 60 patients in each group with local anes-
thetic alone or local anesthetic and steroids. The inclusion criteria was based upon a positive 
response to diagnostic controlled, comparative local anesthetic lumbar facet joint blocks. 
Outcome measures included the numeric rating scale (NRS), Oswestry Disability Index 
(ODI), opioid intake, and work status, at baseline, 3, 6, 12, 18, and 24 months. 
Results: Significant improvement with significant pain relief of ≥ 50% and functional im-
provement of ≥ 40% were observed in 85% in Group 1, and 90% in Group II, at 2-year fol-
low-up. 
The patients in the study experienced significant pain relief for 82 to 84 weeks of 104 weeks, 
requiring approximately 5 to 6 treatments with an average relief of 19 weeks per episode of 
treatment. 
Conclusions: Therapeutic lumbar facet joint nerve blocks, with or without steroids, may 
provide a management option for chronic function-limiting low back pain of facet joint origin. 
Key words: Chronic low back pain, lumbar facet or zygapophysial joint pain, facet joint nerve or 
medial branch blocks, comparative controlled local anesthetic blocks, therapeutic lumbar facet joint 
nerve blocks Int. J. Med. Sci. 2010, 7 
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Introduction 
Recent investigations1 have reported the rising 
prevalence of chronic low back pain. Freburger et al1 
showed an increasing prevalence of chronic impairing 
low back pain over a 14-year interval from 3.9% in 
1992 to 10.2% in 2006 – an overall increase in the pre-
valence of low back pain of 162% with an annual in-
crease of 11.6%. The widely held belief that most of 
the episodes of low back pain will be short-lived, with 
80% to 90% of these attacks resolving in about 6 
weeks,2,3 has been questioned.1,4-8 
  Multiple structures in the lumbar spine includ-
ing discs, facet joints, and sacroiliac joints have been 
considered the major sources of pain in the low back 
and/or lower extremities. Lumbar facet joints have 
been implicated as the source of chronic pain in 21% 
to 41% (with an overall prevalence of 31%) in a hete-
rogenous population with chronic low back pain9-18 
utilizing controlled comparative local anesthetic 
blocks with 80% pain relief and the ability to perform 
previously painful movements as the criterion stan-
dard. Further, based on the responses to controlled 
diagnostic blocks, false-positive rates of 17% to 19% 
have been established with an overall false-positive 
rate of 30%.9-14,16-18 Datta et al9 established Level I or 
II-1 evidence for the diagnostic accuracy of controlled 
facet joint nerve blocks based on the United States 
Preventive Services Task Force (USPSTF) criteria.19 In 
addition, Rubinstein and van Tulder20 concluded that 
there is strong evidence for the diagnostic accuracy of 
lumbar facet joint blocks in evaluating low back pain. 
 Significant controversy surrounds the appropri-
ate management of lumbar facet joint pain, with mul-
tiple therapeutic techniques established in managing 
chronic low back pain.9,10,21-23 The systematic review 
by Datta et al9 provided Level III (limited) evidence 
for lumbar intraarticular injections,24,25 Level II-1 evi-
dence for lumbar facet joint nerve blocks,26-28 and 
Level II-2 evidence for lumbar radiofrequency neu-
rotomy.29-31 The exact mechanism of the therapeutic 
effect of lumbar facet joint nerve blocks is not known, 
whereas radiofrequency neurotomy causes denatur-
ing of the nerves. Consequently, with radiofrequency 
the pain returns when the axons regenerate requiring 
repetition of the radiofrequency procedure. Similarly, 
lumbar facet joint nerve blocks may be repeated to 
reinstate pain relief without any deleterious effects. 
The basis for intraarticular injections has been the 
inflammation of the joint.  
  This report consists of the 2-year results of the 
comparativeness of lumbar facet joint nerve blocks 
with or without steroids evaluated in a randomized, 
double-blind, controlled trial in patients with a con-
firmed diagnosis of lumbar facet joint pain by means 
of comparative, controlled, local anesthetic blocks 
based on modified International Association for the 
Study of Pain (IASP) criteria, with 80% pain relief and 
ability to perform previously painful movements.9-11,32 
Materials and Methods 
  The study was conducted at an interventional 
pain management practice, a specialty referral center, 
in a private practice setting in the United States. The 
study was performed based on Consolidated Stan-
dards of Reporting Trials (CONSORT) guidelines.33,34 
The study protocol was approved by the Institutional 
Review Board (IRB) and the study has been registered 
with the clinical trial registry as NCT00355914. 
Participants 
  One hundred twenty patients were assigned to 
one of the 2 groups consisting of either a non-steroid 
group (Group I) or a steroid group (Group II). Both 
groups were also divided into 2 categories each with 
the addition of Sarapin. Both groups received bupi-
vacaine with or without steroid, however, category B 
patients also received Sarapin in both groups. All 
mixtures consisted of clear solutions. Bupivacaine and 
Sarapin were mixed in equal volumes, and 0.15 mg of 
non-particulate betamethasone was added per mL of 
solution.  
Inclusion and Exclusion Criteria 
  Inclusion criteria consisted of those patients 
with a history of chronic function-limiting low back 
pain of at least 6 months duration, 18 years of age, 
who were able to provide voluntary informed con-
sent, willing to participate in the study as well as the 
follow-up, with positive results to controlled diag-
nostic lumbar facet joint nerve blocks with at least 
80% concordant pain relief and the ability to perform 
previously painful movements. 
  For diagnostic lumbar facet joint interventions 
the exclusion criteria included radicular pain, surgical 
interventions of the lumbar spine within the last 3 
months, uncontrolled major depression or psychiatric 
disorders, heavy opioid usage (morphine equivalent 
of 300 mg), acute or uncontrolled medical illness, 
chronic severe conditions that could interfere with the 
interpretations of the outcome assessments, women 
who were pregnant or lactating, patients unable to be 
positioned in the prone position, and patients with a 
history of adverse reactions to local anesthetic, Sara-
pin, or steroids. Int. J. Med. Sci. 2010, 7 
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Interventions 
  All of the patients were provided with the in-
formed consent and protocol approved by the IRB, 
which described the details of the trial including side 
effects and the mechanisms of withdrawal from the 
study.  
Diagnostic Lumbar Facet Joint Nerve Blocks 
  All patients included in the study underwent 
controlled comparative local anesthetic blocks with 
0.5 mL of 1% preservative-free lidocaine, followed by 
0.5 mL of 0.25% bupivacaine on a separate occasion, 
usually 3 to 4 weeks after the first injection, if the re-
sults of the lidocaine block were positive. All of the 
procedures were performed in a sterile operating 
room, with intermittent fluoroscopic visualization, 
with intravenous access, and light sedation with mi-
dazolam being offered to all patients. A response was 
considered positive if there was 80% pain relief of at 
least 2 hours for lidocaine and 3 hours for bupivacaine 
and greater than the duration of relief with lidocaine, 
and the ability to perform multiple maneuvers which 
were painful prior to the diagnostic facet joint blocks. 
All other types of responses were considered nega-
tive; however, the diagnostic phase was not part of 
the study. 
Therapeutic Lumbar Facet Joint Nerve Blocks 
  In the therapeutic phase, patients were treated 
with lumbar facet joint nerve blocks under fluoros-
copy in a sterile operating room with the injection of a 
0.5 to 1.5 mL mixture at each level as assigned by 
grouping.  
Additional Interventions 
Patients were followed at 3-month intervals un-
less otherwise indicated and lumbar facet joint nerve 
blocks were repeated based on the response to the 
prior interventions with improvement in physical and 
functional status. Lumbar facet joint nerve blocks 
were repeated only when the reported pain levels 
deteriorated to below 50%, with initial report of sig-
nificant pain relief of 50% or more after the previous 
block. The non-responsive patients receiving other 
types of treatments after stopping therapeutic lumbar 
facet joint nerve blocks were considered to be with-
drawn from the study, and no subsequent data were 
collected. 
Co-Interventions 
  All patients were provided with the same 
co-interventions as needed with opioid and 
non-opioid analgesics, adjuvant analgesics, and pre-
viously directed exercise programs prior to enroll-
ment in the study. The adjustments in medical thera-
py were carried out based on the response to injection 
therapy and physical and functional needs. However, 
no specific co-interventions such as physical therapy 
or occupational therapy were provided. 
Objective 
 The objective of this randomized, double-blind, 
controlled trial is to determine the clinical effective-
ness of therapeutic lumbar facet joint nerve blocks 
with local anesthetic with or without steroids in 
managing chronic low back pain of facet joint origin.  
Outcomes  
 Outcome measures included the numeric rating 
scale (NRS), Oswestry Disability Index 2.0 (ODI), 
employment status, and opioid intake, with assess-
ment at 3, 6, 12, 18, and 24 months post-treatment.  
NRS represented 0 with no pain and 10 with the 
worst pain imaginable. The ODI was utilized for 
functional assessment. Value, validity, and frequent 
usage have been reported.33,35-42  
Significant pain relief was described as a 50% or 
more reduction in the NRS score, and significant im-
provement in function was described as at least a 40% 
reduction in ODI. 
  Opioid intake was evaluated based on the do-
sage frequency and schedule of the drug, with con-
version of opioid intake into morphine equivalents.43 
  Patients unemployed or employed on a 
part-time basis with limited or no employment due to 
pain were classified as employable. Patients who 
chose not to work, were retired, or were homemakers 
(not working, but not due to pain) were not consi-
dered in the employment pool. 
Sample Size 
 For this evaluation, a sample size of 60 patients 
for each group was chosen. There were no rando-
mized trials available to base the calculation of sample 
size. Further, the sample size was much smaller in 
previous studies of lumbar44 and cervical45 medial 
branch neurotomies. The literature evaluating the 
quality of individual articles has shown a sample size 
of 50 patients in the smallest group as acceptable.46 
Randomization 
 Sixty patients were randomly assigned into each 
group from a total of 120 patients. Among each group, 
30 patients were assigned to each category for Sara-
pin. 
Sequence Generation 
Randomization was carried out in blocks of 20 
patients by a computer-generated random allocations 
sequence.  Int. J. Med. Sci. 2010, 7 
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Allocation Concealment 
Patients were randomized and the drugs were 
prepared appropriately by the operating room nurse 
assisting with the procedure. All drug mixtures ap-
peared to be identical. 
Implementation 
 After the patients had met the inclusion criteria 
one of the 3 nurses assigned as coordinators of the 
study enrolled the participants and assigned partici-
pants to their respective groups. All the patients were 
invited to enroll in the study if they met inclusion 
criteria. 
Blinding 
The random allocation was not revealed to per-
sonnel in the recovery room or to the physician per-
forming the procedure. Study patients were mixed 
with other patients with no specific indication that 
patients were participating in the study. 
 Patients were unblinded if they requested to be 
unblinded or after completing 24 months of the study. 
Patients were provided with an opportunity to dis-
continue or withdraw from the study for lack of pain 
relief or for any other reason. All the patients with loss 
of follow-up were considered to be withdrawn. 
Statistical Methods 
  Chi-squared statistic, Fisher’s exact test, paired 
t-test, and one-way analysis of variance were used to 
analyze the data. 
  Chi-squared statistic was used to test the dif-
ferences in proportions. Fisher’s exact test was used 
wherever the expected value was less than 5; a paired 
t-test was used to compare the pre- and 
post-treatment results of average pain scores and the 
ODI measurements at baseline versus 3, 6, 12, 18, and 
24 months. The t-test was performed for comparison 
of mean scores between groups. One-way analysis of 
variance was used for comparison of means among 
groups. 
  Initially, categories with or without Sarapin in 
each group were analyzed by comparing them to each 
other. Subsequently, local anesthetic and steroid 
group were compared if there were no differences. 
Intent-to-Treat-Analysis 
 An intent-to-treat-analysis was performed on all 
patients utilizing the last follow-up data. Initial data 
were utilized in the patients who dropped out of the 
study without further follow-up after the first treat-
ment. Sensitivity analysis was performed utilizing 
best case, worst case, and last follow-up scores scena-
rios. 
Results 
Participant Flow 
 Figure 1 illustrates the participant flow.  
Recruitment 
  The recruitment period lasted from November 
2003 to July 2006. 
Baseline Data  
Demographic characteristics are illustrated in 
Table 1. There were significant differences between 
Group I and II with respect to height with Group II 
patients taller than Group I patients. This is not ex-
pected to change the outcomes.  
The number of joints involved was as follows: 2 
joints were involved in 70% of the patients and 3 joints 
were involved in 30% of the patients. Bilateral in-
volvement was seen in 79% of the patients. 
 
Table 1. Demographic characteristics.  
    Group I 
(local anesthetic 
without steroids) 
(N = 60) 
Group II 
(local anesthetic 
with steroids) 
(N = 60) 
Gender  Male  35% (21) 45%  (27) 
Female  65% (39) 55%  (33) 
Age   Mean ± 
SD 
48 ± 15 46  ± 17 
Height (inch-
es) 
Mean ± 
SD 
66 ± 3.8 68*  ± 4.1 
Weight 
(pounds) 
Mean ± 
SD 
183 ± 48  189 ± 50 
Duration of 
pain (months) 
Mean ± 
SD 
108 ± 102  108 ± 94 
Mode of onset 
of pain  
Gradual  52% (31) 62%  (37) 
Sudden  16% (10) 5%  (3) 
WC/MVA 32% (19) 33%  (20) 
H/O of pre-
vious lumbar 
surgery  
  20% (112)  13% (8) 
Group I = bupivacaine with or without Sarapin  
Group II = bupivacaine and steroids with or without Sarapin  
WC = Workers compensation 
MVA = Motor vehicle injury 
 
 
Analysis of Data 
Numbers Analyzed 
 Data were analyzed for both categories in each 
group to evaluate the influence of Sarapin. There were 
no significant differences. Thus, descriptions are pro-
vided for the 2 groups with local anesthetic with or 
without steroid.  
Figure 1 illustrates details of patient follow-up 
and intent-to-treat analysis.  
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Table 5. Functional assessment evaluated by Oswestry Disability Index scores (Mean ± SD). 
  Group I 
(local anesthetic without steroids) 
(N = 60) 
Group II 
(local anesthetic with steroids) 
(N = 60) 
Baseline  26.6 ± 4.6  25.9 ± 5.0 
3 months  12.7* ± 4.7  13.5* ± 5.6 
6 months  12.7* ± 4.7  12.2* ± 5.0 
12 months  12.3* ± 4.8  12.0* ± 5.4 
18 months  12.1* ± 5.0  11.2* ± 4.9 
24 months  12.0* ± 4.9  11.0* ± 4.8 
* indicates significant difference with baseline values  
Group I = bupivacaine with or without Sarapin  
Group II = bupivacaine and steroids with or without Sarapin 
 
Table 6. Daily opioid intake in mg of morphine equivalents. 
  Group I  Group II  P value 
Baseline  31 ± 25.2  37 ± 40.4  0.294 
12 months  29 ± 25.6  33 ± 31.1  0.410 
24 months  27 ± 23.8  30 ± 27.1  0.549 
 
Table 7. Employment characteristics. 
Employment status  Group I 
(local anesthetic without steroids) 
(N = 60) 
Group II 
(local anesthetic with steroids) 
(N = 60) 
Baseline 12  months  24 months  Baseline  12 months  24 months  
Employed part-time   4  4  4  4  2 0 
Employed full-time  6  12  12  13  20 22 
Total Employed 10  16  16  17  22 22 
Unemployed   6  1  2  6  3 2 
Housewife  7 4  3  3  2 3 
Disabled   29  30  30  25  24 25 
Over 65 year of age 8  9  9  9  9 8* 
Total not working  50  44  44  43  38 38 
Total Number of Patients   60  60  60  60  60 60 
* 1 patient over age of 65 returned to work 
Group I = bupivacaine with or without Sarapin  
Group II = bupivacaine and steroids with or without Sarapin 
 
Discussion 
  This randomized, double-blind, controlled trial 
comprised 120 patients with chronic function-limiting 
low back pain of facet joint origin who were treated 
with therapeutic lumbar facet joint nerve blocks. Sig-
nificant pain relief was shown in 85% of Group I and 
90% of Group II at the end of the 2 year study period. 
No significant differences were noted whether pa-
tients received treatment with local anesthetic only or 
local anesthetic and steroids. In addition, functional 
assessment as measured by ODI also showed signifi-
cant improvement, with at least a 40% reduction in 
disability scores in 87% of patients in Group I and 88% 
of patients in Group II. Over the 2 year period, the 
average pain relief per procedure was 19 weeks; the 
average number of procedures was 5-6; total relief 
lasted 82 to 84 weeks. The results of employment 
status and opioid reduction were not significant. Pain 
relief and improvement in functional status were sig-
nificant. Strict criteria were used for diagnosing facet 
joint pain; controlled, comparative local anesthetic 
blocks were used, thus avoiding criticism of including 
patients without facet joint pain in the study. Overall 
the results of the current study are similar to previous 
studies.26-28 There are no other studies available, either 
observational or randomized, evaluating the thera-
peutic role of lumbar facet joint nerve blocks with a 
long-term follow-up of at least 2 years.  
  In this randomized, double-blind, controlled 
trial we found that the 2 drugs used in combination 
with local anesthetic, namely Sarapin and steroid, did 
not differ significantly in their response. The small 
differences between the 2 treatments are unlikely to 
be of clinical importance even in larger studies.  Int. J. Med. Sci. 2010, 7 
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The lack of placebo control could be criticized as 
a drawback. Placebo control in any neural blockade is 
an extremely difficult task. In the United States, it also 
adds ethical issues and difficulty with recruitment. 
What has been described as placebo control has been 
met with design flaws. The effect of any solution in-
jected into a closed space such as an intraarticular 
space or epidural space or over a nerve has not been 
appropriately evaluated. Carette et al24 showed that 
patients responded similarly to an intraarticular in-
jection whether it contained a sodium chloride solu-
tion or local anesthetic with steroid; however, the re-
sponse was low in both groups. Thus, their study 
shows that sodium chloride solution injected into an 
intraarticular space has similar effects as local anes-
thetic with steroids; the conclusion is that intraarticu-
lar steroids are not an effective therapy. The issue is 
also exemplified by the fact that Birkenmaier et al47, 
utilizing either pericapsular injections or medial 
branch blocks, went on to perform cryoneurolysis. 
Not surprisingly, the results were superior in patients 
who were diagnosed using medial branch blocks ra-
ther than pericapsular injections of local anesthetic. 
This study was the basis for Chou et al48 to discard the 
value of diagnostic lumbar facet joint nerve blocks. In 
addition, the literature shows differing effects with 
injections of various solutions such as local anesthetic, 
normal saline, or dextrose and also shows differing 
effects by injection into either the disc, facet joint, or 
multifidus muscle.49-55 It has been shown that a small 
volume of local anesthetic or normal saline abolishes 
muscle twitch induced by a low current 0.5 (mA) 
during electrolocation.49-51 Further, there is direct 
evidence for spinal cord involvement in placebo 
analgesia.52  
The difference between 2 placebo injections of a 
sodium chloride solution and dextrose has been 
shown.49 The experimental and clinical findings from 
investigation of the electrophysiological effects of 
0.9% sodium chloride and dextrose 5% in water solu-
tion have added new knowledge and controversy to 
multiple aspects of neural stimulation used in region-
al anesthesia. The potential inaccuracy created by 
0.9% sodium chloride solution versus 5% dextrose has 
been described.49,55 Further, the evidence also has 
shown differing effects of sodium chloride solution 
when injected into the disc, the facet joint, or paras-
pinal muscles.53,54 Indahl et al53,54 studied the elec-
tromyographic response of the porcine multifidus 
musculature after nerve stimulation,54 and interaction 
among the porcine lumbar intervertebral disc, zyga-
pophysial joints, and paraspinal muscles.53 They 
showed that stimulation of the disc and the facet joint 
capsule produced contractions in the multifidus fas-
cicles.54 They also demonstrated that the introduction 
of lidocaine into the facet joint resulted in a signifi-
cantly reduced electromyographic response, with the 
most drastic reduction seen when stimulating the fa-
cet joint capsule. Surprisingly, they53 also showed that 
the introduction of physiologic saline into the zyga-
pophysial joint reduced the stimulation pathway from 
the intervertebral disc to the paraspinal musculature. 
Consequently, they hypothesized that the paraspinal 
muscle activation caused by nerve stimulation in the 
annulus fibrosus of a lumbar intervertebral disc could 
be altered by saline injection into the zygapophysial 
joint. 
 The evidence cited above leads to the conclusion 
that the effect of local anesthetic on lumbar facet joint 
nerve blocks cannot be attributed to placebo effect, 
even though it has been misinterpreted by some.56 
Recent articles concerning vertebroplasty57,58 have 
generated further interest in placebo control trials. 
However, in neither group, even though they were 
randomized, were the results long lasting; this is in 
addition to other criticisms of the design, etc.59-63 
Consequently, placebo effects are not expected to be 
seen in a high proportion of patients nor are they ex-
pected to be long lasting with repeat interventions 
over a period of 2 years. However, the limitations of 
the lack of placebo must not be underestimated. If 
feasible, a placebo-controlled study with appropriate 
design that includes not injecting the placebo solution 
over the facet joint nerves, and the subsequent results, 
would be highly valid and provide conclusive know-
ledge on the issue of placebo controlled blocks. 
The present study resolves the issue of adding 
Sarapin and steroid to local anesthetic for therapeutic 
lumbar facet joint nerve blocks. In the past, conflicting 
results have been reported.64,65 The basis for intraar-
ticular injections has always been that inflammation is 
present, and that steroids should be used to treat the 
inflammation. However, with lumbar facet joint nerve 
blocks, no such claims have been made either about 
the presence or reduction of inflammation with the 
blockade. The present study shows equal effective-
ness for local anesthetics with or without steroid, in-
dicating a lack of support for the proposition of in-
flammation. The literature is replete with descriptions 
of epidural corticosteroid injections providing a cer-
tain level of efficacy by their anti-inflammatory, im-
muno-suppressive, anti-edema effects, as well as the 
inhibition of neurotransmission within the 
C-fibers.66-69 At the same time, local anesthetics also 
have been described as providing long-term symp-
tomatic relief, even though the mechanism of action 
continues to be an enigma.69-71 Local anesthetics have 
been postulated to provide relief by various mechan-Int. J. Med. Sci. 2010, 7 
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isms including suppression of nociceptive discharge,70 
the blockade of the axonal transport,72,73 the block of 
the sympathetic reflex arc and sensitization,74,75 and 
anti-inflammatory effects.76 The long-term effective-
ness of local anesthetics has been shown in a host of 
previous studies as a result of local anesthetic nerve 
blocks or epidural injections.36,38-42,77 
 A review of the literature shows that the present 
study is the largest to evaluate the effectiveness of 
lumbar facet joint nerve blocks in a randomized con-
trolled trial (though not placebo controlled) with a 
2-year follow-up. The argument that the same drugs 
are used for diagnostic and therapeutic blocks has no 
relevance. This is similar to transforaminal epidural 
injections wherein the same local anesthetic is utilized 
for both diagnosis and therapy. 
  In summary, the results present a real-world 
example describing patients in a private interven-
tional pain management practice setting, with results 
generalizable to similar settings. However, the results 
are not applicable to the general population unless the 
same methodology is used for both diagnosis and 
therapy. The generalizability of the findings of this 
study might only be feasible if studies are published 
using large populations in multiple settings. 
Conclusion 
 The evidence in this report demonstrates lumbar 
facet joint pain diagnosed by controlled, comparative 
local anesthetic blocks may be treated with lumbar 
facet joint nerve blocks either with or without steroid.  
Acknowledgments 
The authors wish to thank Sekar Edem for his 
assistance in the literature search; and Tonie M. Hat-
ton and Diane E. Neihoff, transcriptionists, for their 
assistance in the preparation of this manuscript. 
Conflicts of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Freburger JK, Holmes GM, Agans RP, et al. The rising preva-
lence of chronic low back pain. Arch Intern Med. 2009; 169: 
251-8. 
2.  Shekelle PG, Markovich M, Louie R. An epidemiologic study of 
episodes of back pain care. Spine (Phila Pa 1976). 1995; 20: 
1668-73. 
3.  Anderson GBJ, Svensson HO. The intensity of work recovery in 
low back pain. Spine (Phila Pa 1976). 1983; 8: 880-7. 
4.  Gureje O, Simon GE, von Korff M. A cross-national study of the 
course of persistent pain in primary care. Pain. 2001; 92: 
195-200. 
5.  Kadam UT, Thomas E, Croft PR. Is chronic widespread pain a 
predictor of all-cause morbidity? A 3 year prospective popula-
tion based study in family practice. J Rheumatol. 2005; 32: 
1341-48. 
6.  Cassidy JD, Côté P, Carroll LJ, et al. Incidence and course of low 
back pain episodes in the general population. Spine (Phila Pa 
1976). 2005; 30: 2817-23. 
7.  Enthoven P, Skargren E, Oberg B. Clinical course in patients 
seeking primary care for back or neck pain: A prospective 
5-year follow-up of outcome and health care consumption with 
subgroup analysis. Spine (Phila Pa 1976). 2004; 29: 2458-65. 
8.  Miedema HS, Chorus AM, Wevers CW, et al. Chronicity of back 
problems during working life. Spine (Phila Pa 1976). 1998; 23: 
2021-28. 
9.  Datta S, Lee M, Falco FJE, et al. Systematic assessment of diag-
nostic accuracy and therapeutic utility of lumbar facet joint in-
terventions. Pain Physician. 2009; 12: 437-60. 
10. Manchikanti L, Boswell MV, Singh V, et al. Comprehensive 
evidence-based guidelines for interventional techniques in the 
management of chronic spinal pain. Pain Physician. 2009; 12: 
699-802. 
11. Manchikanti L, Boswell MV, Singh V, et al. Comprehensive 
review of neurophysiologic basis and diagnostic interventions 
in managing chronic spinal pain. Pain Physician. 2009; 12: 
E71-120. 
12.  Manchikanti L, Singh V, Pampati V, et al. Is there correlation of 
facet joint pain in lumbar and cervical spine? Pain Physician. 
2002; 5: 365-71. 
13.  Manchikanti L, Boswell MV, Singh V, et al. Prevalence of facet 
joint pain in chronic spinal pain of cervical, thoracic, and lum-
bar regions. BMC Musculoskelet Disord. 2004; 5: 15. 
14. Manchukonda R, Manchikanti KN, Cash KA, et al. Facet joint 
pain in chronic spinal pain: An evaluation of prevalence and 
false-positive rate of diagnostic blocks. J Spinal Disord Tech. 
2007; 20: 539-45. 
15. Schwarzer AC, Wang SC, Bogduk N, et al. Prevalence and 
clinical features of lumbar zygapophysial joint pain: A study in 
an Australian population with chronic low back pain. Ann 
Rheum Dis. 1995; 54: 100-6.  
16. Manchikanti L, Singh V, Pampati V, et al. Evaluation of the 
relative contributions of various structures in chronic low back 
pain. Pain Physician. 2001; 4: 308-16. 
17.  Manchikanti L, Hirsch JA, Pampati V. Chronic low back pain of 
facet (zygapophysial) joint origin: Is there a difference based on 
involvement of single or multiple spinal regions? Pain Physi-
cian. 2003; 6: 399-405. 
18.  Manchikanti L, Manchukonda R, Pampati V, et al. Prevalence of 
facet joint pain in chronic low back pain in postsurgical patients 
by controlled comparative local anesthetic blocks. Arch Phys 
Med Rehabil. 2007; 88: 449-55. 
19. Berg AO, Allan JD. Introducing the third U.S. Preventive Ser-
vices Task Force. Am J Prev Med. 2001; 20: S3-4. 
20. Rubinstein SM, van Tulder M. A best-evidence review of di-
agnostic procedures for neck and low-back pain. Best Pract Res 
Clin Rheumatol. 2008; 22: 471-82. 
21. Manchikanti L, Boswell MV, Datta S, et al. Comprehensive 
review of therapeutic interventions in managing chronic spinal 
pain. Pain Physician. 2009; 12: E123-98. 
22. Chou R, Atlas SJ, Stanos SP, Rosenquist RW. Nonsurgical in-
terventional therapies for low back pain: A review of the evi-
dence for an American Pain Society clinical practice guideline. 
Spine (Phila Pa 1976). 2009; 34: 1078-93. 
23.   Staal JB, de Bie RA, de Vet HC, et al. Injection therapy for sub-
acute and chronic low back pain: An updated Cochrane review. 
Spine (Phila Pa 1976). 2009; 34: 49-59. 
24. Carette S, Marcoux S, Truchon R, et al. A controlled trial of 
corticosteroid injections into facet joints for chronic low back 
pain. N Engl J Med. 1991; 325: 1002-7. Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
134
25.  Schulte TL, Pietila TA, Heidenreich J, et al. Injection therapy of 
lumbar facet syndrome: A prospective study. Acta Neurochir 
(Wien). 2006; 148: 1165-72. 
26. Manchikanti L, Singh V, Falco FJE, et al. Lumbar facet joint 
nerve blocks in managing chronic facet joint pain: One-year 
follow-up of a randomized, double-blind controlled trial: Clin-
ical Trial NCT00355914. Pain Physician. 2008; 11: 121-32. 
27. Manchikanti L, Manchikanti KN, Manchukonda R, et al. Eval-
uation of lumbar facet joint nerve blocks in the management of 
chronic low back pain: A preliminary report of a randomized, 
double-blind controlled trial. Clinical Trial NCT000355914. Pain 
Physician. 2007; 10: 425-40. 
28. Manchikanti L, Pampati V, Bakhit CE, et al. Effectiveness of 
lumbar facet joint nerve blocks in chronic low back pain: A 
randomized clinical trial. Pain Physician. 2001; 4: 101-17. 
29. Nath S, Nath CA, Pettersson K. Percutaneous lumbar zyga-
pophysial (facet) joint neurotomy using radiofrequency current, 
in the management of chronic low back pain. A randomized 
double-blind trial. Spine (Phila Pa 1976). 2008; 33: 1291-7. 
30. Gofeld M, Jitendra J, Faclier G. Radiofrequency facet denerva-
tion of the lumbar zygapophysial joints: 10-year prospective 
clinical audit. Pain Physician. 2007; 10: 291-300. 
31.  Dreyfuss P, Halbrook B, Pauza K, et al. Efficacy and validity of 
radiofrequency neurotomy for chronic lumbar zygapophysial 
joint pain. Spine (Phila Pa 1976). 2000; 25: 1270-7. 
32. Merskey H, Bogduk N. Lumbar zygapophysial joint pain. In:  
Classification of Chronic Pain; Descriptions of Chronic Pain 
Syndromes and Definition of Pain Terms, 2nd ed; Task Force on 
Taxonomy of the International Association for the Study of 
Pain. Seattle: IASP Press. 1994: 181-2. 
33. Altman DG, Schulz KF, Moher D, et al; CONSORT GROUP 
(Consolidated Standards of Reporting Trials). The revised 
CONSORT statement for reporting randomized trials: Expla-
nation and elaboration. Ann Intern Med. 2001; 134: 663-94. 
34.  Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 expla-
nation and elaboration: Updated guidelines for reporting pa-
rallel group randomised trials. BMJ. 2010; 340: c869. 
35.  Fairbank JCT, Pynsent PB. The Oswestry disability index. Spine 
(Phila Pa 1976). 2000; 25: 2940-53. 
36.  Manchikanti L, Singh V, Falco FJE, et al. Cervical medial branch 
blocks for chronic cervical facet joint pain: A randomized 
double-blind, controlled trial with one-year follow-up. Spine 
(Phila PA 1976). 2008; 33: 1813-20. 
37.  Manchikanti L, Hirsch JA, Smith HS. Evidence-based medicine, 
systematic reviews, and guidelines in interventional pain 
management: Part 2: Randomized controlled trials. Pain Physi-
cian. 2008; 11: 717-73. 
38. Manchikanti L, Singh V, Falco FJE, et al. Effectiveness of tho-
racic medial branch blocks in managing chronic pain: A pre-
liminary report of a randomized, double-blind controlled trial; 
Clinical trial NCT00355706. Pain Physician. 2008; 11: 491-504. 
39. Manchikanti L, Cash KA, McManus CD, et al. Preliminary 
results of randomized, equivalence trial of fluoroscopic caudal 
epidural injections in managing chronic low back pain: Part 1. 
Discogenic pain without disc herniation or radiculitis. Pain 
Physician. 2008; 11: 785-800. 
40.  Manchikanti L, Singh V, Cash KA, et al. Preliminary results of 
randomized, equivalence trial of fluoroscopic caudal epidural 
injections in managing chronic low back pain: Part 2. Disc her-
niation and radiculitis. Pain Physician. 2008; 11: 801-15. 
41.  Manchikanti L, Singh V, Cash KA, et al. Preliminary results of 
randomized, equivalence trial of fluoroscopic caudal epidural 
injections in managing chronic low back pain: Part 3. Post sur-
gery syndrome. Pain Physician. 2008; 11: 817-31. 
42. Manchikanti L, Cash KA, McManus CD, et al. Preliminary 
results of randomized, equivalence trial of fluoroscopic caudal 
epidural injections in managing chronic low back pain: Part 4. 
Spinal stenosis. Pain Physician. 2008; 11: 833-48. 
43. Pereira J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios 
for opioids. A critical review and proposals for long-term dos-
ing. J Pain Symptom Manage. 2001; 22: 672-87.  
44.  van Kleef M, Barendse GA, Kessels A, et al. Randomized trial of 
radiofrequency lumbar facet denervation for chronic low back 
pain. Spine (Phila Pa 1976). 1999; 24: 1937-42. 
45. Lord SM, Barnsley L, Wallis BJ, et al. Percutaneous radiofre-
quency neurotomy for chronic cervical zygapophysial joint 
pain. N Engl J Med. 1996; 335: 1721-6. 
46.  Koes BW, Scholten RJ, Mens JM, et al. Efficacy of epidural ste-
roid injections for low-back pain and sciatica: A systematic re-
view of randomized clinical trials. Pain. 1995; 63: 279-88. 
47. Birkenmaier C, Veihelmann A, Trouillier HH, et al. Medial 
branch blocks versus pericapsular blocks in selecting patients 
for percutaneous cryodenervation of lumbar facet joints. Reg 
Anesth Pain Med. 2007; 32: 27-33. 
48.  [Internet] Chou R, Huffman L. Guideline for the Evaluation and 
Management of Low Back Pain: Evidence Review. American 
Pain Society, Glenview, IL, 2009. 
www.ampainsoc.org/pub/pdf/LBPEvidRev.pdf  
49. Tsui BC, Wagner A, Finucane B. Electrophysiologic effect of 
injectates on peripheral nerve stimulation. Reg Anesth Pain 
Med. 2004; 29: 189-93. 
50.  Pham Dang C, Lelong A, Guilley J, et al. Effect on neurostimu-
lation of injectates used for perineural space expansion before 
placement of a stimulation catheter: Normal saline versus dex-
trose 5% in water. Reg Anesth Pain Med. 2009; 34: 398-403. 
51.  Johnson CR, Barr RC, Klein SM. A computer model of electrical 
stimulation of peripheral nerves in regional anesthesia. Anes-
thesiology. 2007; 106: 323-30. 
52. Eippert F, Finsterbusch J, Bingel U, et al. Direct evidence for 
spinal cord involvement in placebo analgesia. Science. 2009; 
326: 404. 
53.  Indahl A, Kaigle AM, Reikeräs O, et al. Interaction between the 
porcine lumbar intervertebral disc, zygapophysial joints, and 
paraspinal muscles. Spine (Phila Pa 1976). 1997, 22: 2834-40. 
54. Indahl A, Kaigle A, Reikeräs O, et al. Electromyographic re-
sponse of the porcine multifidus musculature after nerve sti-
mulation. Spine (Phila Pa 1976). 1995, 20: 2652-8. 
55.  Tsui BC, Kropelin B, Ganapathy S, et al. Dextrose 5% in water: 
Fluid medium maintaining electrical stimulation of peripheral 
nerve during stimulating catheter placement. Acta Anaesthesiol 
Scand. 2005, 49: 1562-5. 
56.  Levin JH. Prospective, double-blind, randomized place-
bo-controlled trials in interventional spine: What the highest 
quality literature tells us. Spine J. 2009; 9: 690-703. 
57. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized 
trial of vertebroplasty for painful osteoporotic vertebral frac-
tures. N Engl J Med. 2009; 361: 557-68. 
58. Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized 
trial of vertebroplasty for osteoporotic spinal fractures. N Engl J 
Med. 2009; 361: 569-79. 
59. Weinstein JN. Balancing science and informed choice in deci-
sions about vertebroplasty. N Engl J Med. 2009; 361: 619-21. 
60.  Clark W, Lyon S, Burnes J. Trials of vertebroplasty for vertebral 
factures. N Engl J Med. 2009; 361: 2097-8. 
61.  Baerlocher MO, Munk PL, Liu DM. Trials of vertebroplasty for 
fractures. N Engl J Med. 2009; 361: 2098. 
62.  Lotz JC. Trials of vertebroplasty for vertebral fractures. N Engl J 
Med. 2009; 361: 2098. 
63. Grey A, Bolland M. Trials of vertebroplasty for vertebral frac-
tures. N Engl J Med. 2009; 361: 2098-9. 
64. Manchikanti L, Pampati V, Fellows B, et al. The diagnostic 
validity and therapeutic value of lumbar facet joint nerve blocks 
with or without adjuvant agents. Curr Rev Pain. 2000; 4: 337-44. Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
135
65.  Manchikanti KN, Pampati V, Damron KS, et al. A double-blind, 
controlled evaluation of the value of Sarapin in neural block-
ade. Pain Physician. 2004; 7: 59-62. 
66.  Hayashi N, Weinstein JN, Meller ST, et al. The effect of epidural 
injection of betamethasone or bupivacaine in a rat model of 
lumbar radiculopathy. Spine (Phila Pa 1976). 1998; 23: 877-85. 
67.  Lee HM, Weinstein JN, Meller ST, et al. The role of steroids and 
their effects on phospholipase A2. An animal model of radicu-
lopathy. Spine (Phila Pa 1976). 1998; 23: 1191-6. 
68.  Johansson A, Hao J, Sjolund B. Local corticosteroid application 
blocks transmission in normal nociceptive C-fibres. Acta 
Anaesthesiol Scand. 1990; 34: 335-8. 
69. Pasqualucci A, Varrassi G, Braschi A, et al. Epidural local 
anesthetic plus corticosteroid for the treatment of cervical 
brachial radicular pain: Single injection verus continuous infu-
sion. Clin J Pain. 2007; 23: 551-7. 
70. Arner S, Lindblom U, Meyerson BA, et al. Prolonged relief of 
neuralgia after regional anesthetic block. A call for further ex-
perimental and systematic clinical studies. Pain. 1990; 43: 
287-97. 
71. Wertheim HM, Rovenstine EA. Suprascapular nerve block. 
Anesthesiology. 1941; 2: 541-5. 
72. Bisby MA. Inhibition of axonal transport in nerves chronically 
treated with local anesthetics. Exp Neurol. 1975; 47: 481-89. 
73. Lavoie PA, Khazen T, Filion PR. Mechanisms of the inhibition 
of fast axonal transport by local anesthetics. Neuropharmacol-
ogy. 1989; 28: 175-81. 
74.  Katz WA, Rothenberg R. The nature of pain: Pathophysiology. J 
Clin Rheumatol. 2005; 11: S11-5. 
75.  Melzack R, Coderre TJ, Katz J, et al. Central neuroplasticity and 
pathological pain. Ann N Y Acad Sci. 2001; 933: 157-74. 
76. Cassuto J, Sinclair R, Bonderovic M. Anti-inflammatory prop-
erties of local anesthetics and their present and potential clinical 
implications. Acta Anaesthesiol Scand. 2006; 50: 265-82. 
77. Riew KD, Park JB, Cho YS, et al. Nerve root blocks in the 
treatment of lumbar radicular pain. A minimum five-year fol-
low-up. J Bone Joint Surg Am. 2006; 88: 1722-5. 